WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "8840be71-21a9-41d1-bc24-b9e15c303db3"}, "_deposit": {"created_by": 3, "id": "31012", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "31012"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00031012", "sets": ["2231"]}, "author_link": ["52745", "47931", "52746", "52747", "36"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-03-03", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "75", "bibliographicVolumeNumber": "11", "bibliographic_titles": [{"bibliographic_title": "Frontiers in Behavioral Neuroscience"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Parkinson’s disease (PD), a neurodegenerative disorder, is accompanied by various non-motor symptoms including depression and anxiety, which may precede the onset of motor symptoms. Selegiline is an irreversible monoamine oxidase-B (MAO-B) inhibitor, and is widely used in the treatment of PD and major depression. However, there are few reports about the effects of selegiline on non-motor symptoms in PD. The aim of this study was to explore the antidepressant and anxiolytic effects of selegiline, using CD157/BST1 knockout (CD157 KO) mouse, a PD-related genetic model displaying depression and anxiety, compared with other antiparkinsonian drugs and an antidepressant, and was to investigate the effects of selegiline on biochemical parameters in emotion-related brain regions. A single administration of selegiline (1–10 mg/kg) dose-dependently reduced immobility time in the forced swimming test (FST) in CD157 KO mice, but not C57BL/6N wild-type (WT) mice. At 10 mg/kg, but not 3 mg/kg, selegiline significantly increased climbing time in CD157 KO mice. A single administration of the antiparkinsonian drugs pramipexole (a dopamine (DA) D2/D3 receptor agonist) or rasagiline (another MAO-B inhibitor), and repeated injections of a noradrenergic and specific serotonergic antidepressant (NaSSA), mirtazapine, also decreased immobility time, but did not increase climbing time, in CD157 KO mice. The antidepressant-like effects of 10 mg/kg selegiline were comparable to those of 10 mg/kg rasagiline, and tended to be stronger than those of 1 mg/kg rasagiline. After the FST, CD157 KO mice showed decreases in striatal and hippocampal serotonin (5-HT) content, cortical norepinephrine (NE) content, and plasma corticosterone concentration. A single administration of selegiline at 10 mg/kg returned striatal 5-HT, cortical NE, and plasma corticosterone levels to those observed in WT mice. In the open field test (OFT), repeated administration of mirtazapine had anxiolytic effects, and selegiline nonsignificantly ameliorated anxiety-like behaviors in CD157 KO mice. In the social interaction and preference tests, repeated mirtazapine ameliorated the high anxiety and low sociability of CD157 KO mice, whereas selegiline did not. These results indicate that selegiline has antidepressant and mild anxiolytic effects in CD157 KO mice, and suggest that it is an effective antiparkinsonian drug for depressive and anxiety symptoms in PD patients with a CD157 single nucleotide polymorphism (SNP). © 2017 Kasai, Yoshihara, Lopatina, Ishihara and Higashida.", "subitem_description_type": "Abstract"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Frontiers Research Foundation"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3389/fnbeh.2017.00075", "subitem_relation_type_select": "DOI"}}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1662-5153", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kasai, Satoka"}], "nameIdentifiers": [{"nameIdentifier": "52745", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshihara, Toru"}], "nameIdentifiers": [{"nameIdentifier": "47931", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "00401935", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=00401935"}, {"nameIdentifier": "00401935", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000000401935"}]}, {"creatorNames": [{"creatorName": "Lopatina, Olga"}], "nameIdentifiers": [{"nameIdentifier": "52746", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishihara, Katsuhiko"}], "nameIdentifiers": [{"nameIdentifier": "52747", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashida, Haruhiro"}], "nameIdentifiers": [{"nameIdentifier": "36", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30093066", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30093066"}, {"nameIdentifier": "30093066", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=30093066"}, {"nameIdentifier": "30093066", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030093066"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2017-10-05"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CH-PR-HIGASHIDA-H-75.pdf", "filesize": [{"value": "3.2 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 3200000.0, "url": {"label": "CH-PR-HIGASHIDA-H-75.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/31012/files/CH-PR-HIGASHIDA-H-75.pdf"}, "version_id": "a20f75f6-8eb1-4637-b879-07299d688766"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "CD157/BST-1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Forced swimming test", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Mirtazapine", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-motor symptoms", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Open field test", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Parkinson’s disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Selegiline", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Selegiline ameliorates depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson’s disease", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Selegiline ameliorates depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson’s disease"}]}, "item_type_id": "4", "owner": "3", "path": ["2231"], "permalink_uri": "http://hdl.handle.net/2297/48596", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-10-05"}, "publish_date": "2017-10-05", "publish_status": "0", "recid": "31012", "relation": {}, "relation_version_is_last": true, "title": ["Selegiline ameliorates depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson’s disease"], "weko_shared_id": -1}
Selegiline ameliorates depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson’s disease
http://hdl.handle.net/2297/48596
http://hdl.handle.net/2297/48596dd44c061-5cf7-4734-a8db-cb163006d55d
名前 / ファイル | ライセンス | アクション |
---|---|---|
CH-PR-HIGASHIDA-H-75.pdf (3.2 MB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-10-05 | |||||
タイトル | ||||||
タイトル | Selegiline ameliorates depression-like behavior in mice lacking the CD157/BST1 gene, a risk factor for Parkinson’s disease | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kasai, Satoka
× Kasai, Satoka× Yoshihara, Toru× Lopatina, Olga× Ishihara, Katsuhiko× Higashida, Haruhiro |
|||||
書誌情報 |
Frontiers in Behavioral Neuroscience 巻 11, p. 75, 発行日 2017-03-03 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1662-5153 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3389/fnbeh.2017.00075 | |||||
出版者 | ||||||
出版者 | Frontiers Research Foundation | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Parkinson’s disease (PD), a neurodegenerative disorder, is accompanied by various non-motor symptoms including depression and anxiety, which may precede the onset of motor symptoms. Selegiline is an irreversible monoamine oxidase-B (MAO-B) inhibitor, and is widely used in the treatment of PD and major depression. However, there are few reports about the effects of selegiline on non-motor symptoms in PD. The aim of this study was to explore the antidepressant and anxiolytic effects of selegiline, using CD157/BST1 knockout (CD157 KO) mouse, a PD-related genetic model displaying depression and anxiety, compared with other antiparkinsonian drugs and an antidepressant, and was to investigate the effects of selegiline on biochemical parameters in emotion-related brain regions. A single administration of selegiline (1–10 mg/kg) dose-dependently reduced immobility time in the forced swimming test (FST) in CD157 KO mice, but not C57BL/6N wild-type (WT) mice. At 10 mg/kg, but not 3 mg/kg, selegiline significantly increased climbing time in CD157 KO mice. A single administration of the antiparkinsonian drugs pramipexole (a dopamine (DA) D2/D3 receptor agonist) or rasagiline (another MAO-B inhibitor), and repeated injections of a noradrenergic and specific serotonergic antidepressant (NaSSA), mirtazapine, also decreased immobility time, but did not increase climbing time, in CD157 KO mice. The antidepressant-like effects of 10 mg/kg selegiline were comparable to those of 10 mg/kg rasagiline, and tended to be stronger than those of 1 mg/kg rasagiline. After the FST, CD157 KO mice showed decreases in striatal and hippocampal serotonin (5-HT) content, cortical norepinephrine (NE) content, and plasma corticosterone concentration. A single administration of selegiline at 10 mg/kg returned striatal 5-HT, cortical NE, and plasma corticosterone levels to those observed in WT mice. In the open field test (OFT), repeated administration of mirtazapine had anxiolytic effects, and selegiline nonsignificantly ameliorated anxiety-like behaviors in CD157 KO mice. In the social interaction and preference tests, repeated mirtazapine ameliorated the high anxiety and low sociability of CD157 KO mice, whereas selegiline did not. These results indicate that selegiline has antidepressant and mild anxiolytic effects in CD157 KO mice, and suggest that it is an effective antiparkinsonian drug for depressive and anxiety symptoms in PD patients with a CD157 single nucleotide polymorphism (SNP). © 2017 Kasai, Yoshihara, Lopatina, Ishihara and Higashida. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 |